CA2520027C - Derives de 2,3,6-trisubstitue 4-pyrimidone - Google Patents

Derives de 2,3,6-trisubstitue 4-pyrimidone Download PDF

Info

Publication number
CA2520027C
CA2520027C CA2520027A CA2520027A CA2520027C CA 2520027 C CA2520027 C CA 2520027C CA 2520027 A CA2520027 A CA 2520027A CA 2520027 A CA2520027 A CA 2520027A CA 2520027 C CA2520027 C CA 2520027C
Authority
CA
Canada
Prior art keywords
group
methyl
pyrimidin
piperazin
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2520027A
Other languages
English (en)
Other versions
CA2520027A1 (fr
Inventor
Kazutoshi Watanabe
Fumiaki Uehara
Shinsuke Hiki
Satoshi Yokoshima
Yoshihiro Usui
Masahiro Okuyama
Aya Shoda
Keiichi Aritomo
Toshiyuki Kohara
Kenji Fukunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Mitsubishi Tanabe Pharma Corp
Original Assignee
Sanofi Aventis France
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Aventis France
Publication of CA2520027A1 publication Critical patent/CA2520027A1/fr
Application granted granted Critical
Publication of CA2520027C publication Critical patent/CA2520027C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2520027A 2003-03-26 2004-03-26 Derives de 2,3,6-trisubstitue 4-pyrimidone Expired - Fee Related CA2520027C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2003126021 2003-03-26
JP2003-126022 2003-03-26
JP2003-126021 2003-03-26
JP2003126022 2003-03-26
PCT/JP2004/004320 WO2004085408A1 (fr) 2003-03-26 2004-03-26 Derives de 2,3,6-trisubstitue 4-pyrimidone

Publications (2)

Publication Number Publication Date
CA2520027A1 CA2520027A1 (fr) 2004-10-07
CA2520027C true CA2520027C (fr) 2011-08-09

Family

ID=33100427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2520027A Expired - Fee Related CA2520027C (fr) 2003-03-26 2004-03-26 Derives de 2,3,6-trisubstitue 4-pyrimidone

Country Status (16)

Country Link
US (1) US7504411B2 (fr)
EP (3) EP2308854A1 (fr)
JP (1) JP4679509B2 (fr)
KR (1) KR100985419B1 (fr)
CN (1) CN1764650B (fr)
AR (1) AR045677A1 (fr)
AU (1) AU2004223987B2 (fr)
BR (1) BRPI0409042A (fr)
CA (1) CA2520027C (fr)
EA (1) EA009620B1 (fr)
HK (1) HK1090368A1 (fr)
IL (1) IL170877A (fr)
NO (1) NO20054952L (fr)
NZ (1) NZ543096A (fr)
TW (1) TWI357408B (fr)
WO (1) WO2004085408A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
MXPA04002662A (es) * 2001-09-21 2004-11-22 Sanofi Aventis Derivados de 3-substituida-4-pirimidona.
AR036604A1 (es) 2001-09-21 2004-09-22 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida
WO2004055007A1 (fr) 2002-12-16 2004-07-01 Mitsubishi Pharma Corporation Derives 4-pyrimidones substitues en 3
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN102134229B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
TW200621760A (en) * 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
ZA200703383B (en) * 2004-09-29 2009-05-27 Mitsubishi Pharma Corp 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
CN101084198A (zh) * 2004-10-15 2007-12-05 阿斯利康(瑞典)有限公司 取代的氨基－嘧啶酮及其用途
US20090221579A1 (en) * 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
ES2435790T3 (es) * 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
WO2006068978A2 (fr) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Inhibiteurs de dipeptidyle peptidase
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
WO2008023239A1 (fr) * 2006-08-23 2008-02-28 Pfizer Products Inc. Composés de pyrimidone en tant qu'inhibiteurs de gsk-3
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
JP5438976B2 (ja) 2007-02-09 2014-03-12 株式会社カネカ 光学活性２−アリールピペラジン誘導体の製造法
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
KR20100051625A (ko) * 2007-06-28 2010-05-17 인터벳 인터내셔널 비.브이. Ｃｂ1 길항제로서의 치환된 피페라진
US20100249144A1 (en) * 2007-06-28 2010-09-30 Demong Duane Eugene Substituted piperazines as cb1 antagonists
MX2010002765A (es) * 2007-09-14 2010-05-19 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-4-ona.
WO2011019089A1 (fr) * 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Dérivés du pyrimidone utilisés comme inhibiteurs de la protéine kinase tau 1
EP2464632A1 (fr) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Dérivés de pyrimidone utilisés en tant qu'inhibiteurs de la protéine kinase tau 1
CN104211635A (zh) * 2013-06-03 2014-12-17 中国科学院上海药物研究所 一类哌啶类化合物及其制备方法、药物组合物和用途
US10246463B2 (en) 2015-04-07 2019-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hypoxia-inducible factor 1 (HIF-1) inhibitors
CN105130904B (zh) * 2015-08-24 2017-10-13 如东众意化工有限公司 一种2‑氰基‑4‑氯‑5‑（4‑甲基苯基）咪唑的合成方法
CN106854189A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种哌嗪化合物的合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US187004A (en) * 1877-02-06 Improvement in water-wheels
US90490A (en) * 1869-05-25 Improved washing-machine
JPS559099B2 (fr) 1972-08-07 1980-03-07
JPS4935633A (fr) 1972-08-09 1974-04-02
JPS5124008B2 (fr) 1972-08-10 1976-07-21
JPS4935632A (fr) 1972-08-10 1974-04-02
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
US4507302A (en) 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
EP0354179B1 (fr) 1988-07-29 1994-08-17 Ciba-Geigy Ag Thiouracils comme stabilisants pour des polymères contenant du chlore
EP0911390B1 (fr) 1991-12-06 2009-08-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protéine kinases comme outils pour le diagnostic et le traitement de la maladie d' Alzheimer
DE4206145A1 (de) 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
AU735901C (en) 1996-12-05 2004-02-12 Amgen, Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
CZ296911B6 (cs) 1996-12-05 2006-07-12 Amgen Inc. Substituovaný pyrimidin, jeho pouzití a farmaceutický prostredek na jeho bázi
WO1998024782A2 (fr) 1996-12-05 1998-06-11 Amgen Inc. Composes pyrimidines substitues et leur utilisation
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
TWI241298B (en) * 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
EP1261327B1 (fr) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Modulateurs de recepteurs de l'adenosine
FR2806723B1 (fr) 2000-03-23 2002-05-10 Sanofi Synthelabo DERIVES D'ACIDE 8-OXO-5,8-DIHYDRO-6H-DIBENZO [a,g] QUINOLIZINE-13-PROPANOIQUE , LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2001070728A1 (fr) 2000-03-23 2001-09-27 Sanofi-Synthelabo Derives de la 2-[azote-heterocyclique]pyrimidone
EP1136482A1 (fr) 2000-03-23 2001-09-26 Sanofi-Synthelabo Dérivés de 2-amino-3-(alkyl)-pyrimidone comme inhibiteurs de GSK3bêta
MXPA04002662A (es) 2001-09-21 2004-11-22 Sanofi Aventis Derivados de 3-substituida-4-pirimidona.
AR036604A1 (es) * 2001-09-21 2004-09-22 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida
JP4653915B2 (ja) * 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
WO2004055007A1 (fr) 2002-12-16 2004-07-01 Mitsubishi Pharma Corporation Derives 4-pyrimidones substitues en 3

Also Published As

Publication number Publication date
AR045677A1 (es) 2005-11-09
AU2004223987B2 (en) 2010-02-18
TWI357408B (en) 2012-02-01
CN1764650A (zh) 2006-04-26
HK1090368A1 (en) 2006-12-22
BRPI0409042A (pt) 2006-03-28
CN1764650B (zh) 2010-06-16
IL170877A (en) 2011-02-28
US20060252768A1 (en) 2006-11-09
JP2006521370A (ja) 2006-09-21
NO20054952L (no) 2005-10-25
KR100985419B1 (ko) 2010-10-05
EA200501516A1 (ru) 2006-04-28
EA009620B1 (ru) 2008-02-28
EP1608630A1 (fr) 2005-12-28
EP2308854A1 (fr) 2011-04-13
CA2520027A1 (fr) 2004-10-07
JP4679509B2 (ja) 2011-04-27
AU2004223987A1 (en) 2004-10-07
EP2305651A1 (fr) 2011-04-06
US7504411B2 (en) 2009-03-17
NZ543096A (en) 2008-07-31
TW200510338A (en) 2005-03-16
WO2004085408A1 (fr) 2004-10-07
KR20050111613A (ko) 2005-11-25

Similar Documents

Publication Publication Date Title
CA2520027C (fr) Derives de 2,3,6-trisubstitue 4-pyrimidone
ES2323576T3 (es) Derivados de 4-pirimidona 3-sustituida.
EP1427709B1 (fr) Derives de 3-substitute-4-pyrimidone
AU2002337498A1 (en) 3-substituted-4-pyrimidone derivatives
AU2002337499A1 (en) 3-substituted-4-pyrimidone derivatives
EA007501B1 (ru) Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение
KR100956052B1 (ko) 3-치환-4-피리미돈 유도체
AU2003285777B2 (en) 3-substituted-4-pyrimidone derivatives
ZA200401845B (en) 3-substituted-4-pyrimidone derivatives.
ZA200507750B (en) 2, 3, 6-trisubstituted-4-pyrimidone derivatives
MXPA05010323A (en) 2, 3, 6-trisubstituted-4-pyrimidone derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140326